Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial
Henrik Watz(University of Lübeck), Peter M.A. Calverley(University of Liverpool), Helen Finnigan(Boehringer Ingelheim (South Korea)), Claus Vogelmeier(German Center for Lung Research), Emiel F.�M. Wouters(Maastricht University), Pascal Chanez(Aix-Marseille Université), H Magnussen(LungenClinic Grosshansdorf), Kay Tetzlaff(Boehringer Ingelheim (Taiwan)), Ronald Dahl(Aarhus University Hospital), Anne Kirsten(German Center for Lung Research), Bernd Disse(Boehringer Ingelheim (Taiwan)), Roberto Rodríguez-Roisin(Centro de Investigación Biomédica en Red de Enfermedades Respiratorias), Leonardo M. Fabbri(University of Ferrara)
Cited by 420
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation
|American Journal of Respiratory and Critical Care Medicine|2013|3.8k
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
|American Journal of Respiratory and Critical Care Medicine|2017|3.2k
Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease
|New England Journal of Medicine|2010|3k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k